| Literature DB >> 31890219 |
Faruk Hadziselimovic1, Gilvydas Verkauskas2, Beata Vincel3, Michael B Stadler4,5.
Abstract
BACKGROUND: Cryptorchidism is a frequent endocrinopathy in boys that has been associated with an increased risk of developing testicular cancer and infertility. The condition is curable by combined surgery and hormonal treatment during early pre-pubertal stages using gonadotropin releasing hormone agonist (GnRHa). However, whether the treatment also alters the expression of testicular long non-coding RNAs (lncRNAs) is unknown. To gain insight into the effect of GnRHa on testicular lncRNA levels, we re-analyzed an expression dataset generated from testicular biopsies obtained during orchidopexy for bilateral cryptorchidism.Entities:
Keywords: Antisense lncRNAs; Cryptorchidism; GnRHa; Male infertility; Mitosis; Spermatogenesis; lincRNAs; lncRNAs
Year: 2019 PMID: 31890219 PMCID: PMC6933710 DOI: 10.1186/s12610-019-0097-3
Source DB: PubMed Journal: Basic Clin Androl ISSN: 2051-4190
Fig. 1Flow chart of the study design and the selection of patients and samples for RNA-sequencing based on expression profiling. High infertility risk (HIR) and low infertility risk (LIR) patients are indicated. Classification is based on the absence (Ad-) or presence (Ad+) of Ad spermatogonia
Fig. 2RNA-sequencing data for lncRNAs. A false color heatmap (red is high, blue is low) shows data from pairs of testes, analyzed. Horizontal bars at the top indicate patient categories and age. Four sample from two HIR patients (p32 and p33; biopsy number) having had surgery “only” treatment; line 1 and 2 during first surgery obtained from ipsilateral testis (I), line 3 and 4 show results from contralateral testis six months after first orchidopexy (II) Buserelin treated patients p5 and p6; line 5 an 6 before treatment and line 7 and 8 contralateral testis after hormonal treatment. Color scales for expression (red/blue) and age (green) are shown
Fig. 3Volcano plots of lncRNA expression ratios: (a) Between the high (HIR) and low infertility risk (LIR) groups or (b) in the HIR group before and after GnRHa treatment. Genes with no significant difference in expression between the two groups compared in each panel are in black. Differentially expressed genes are shown in red. The most upregulated genes on the right, the most downregulated genes on the left, and the most significant genes at the top
Testicular lincRNAs and AS-lncRNAs that increase after GnRHa treatment and are involved in stem cell renewal and differentiation
| Gene ID | RPKM before GnRHa | RPKM after GnRHa | log2FC GnRH | FDR | |
|---|---|---|---|---|---|
| 0.044 / 0.06 | 0.40 / 0.24 | 2,68 | 0,0004 | 0,002 | |
| 0.11 / 0.04 | 1.11 / 0.68 | 2.60 | 3.588E-08 | 4.35E-06 | |
| 0.05 / 0.04 | 0.66 / 0.49 | 2.80 | 0.0001 | 0.001 | |
| 0.22 / 0.07 | 1.25 / 0.45 | 2.57 | 0.0001 | 0.0008 | |
| 0.15 / 0.07 | 0.79 / 0.64 | 2.76 | 0.0002 | 0.001 | |
| 0.04 / 0.03 | 0.35 / 0.25 | 2.72 | 0.0002 | 0.001 | |
| 0.07 / 0.04 | 0.48 / 0.46 | 3.9 | 0.0008 | 0.003 | |
| 0.20 / 0.10 | 1.41 / 0.81 | 2.73 | 5.773E-06 | 0.0001 | |
| 0.15 / 0.03 | 1.32 / 0.70 | 3,36 | 2.078E-09 | 6.43E-07 | |
| 0.25 / 0.04 | 1.84 / 0.45 | 2.89 | 2.049E-09 | 6.43E-07 | |
| 0.09 / 0.06 | 1.26 / 0.67 | 3.60 | 0.0002 | 0.001 | |
| 0.03 / 0.05 | 0.58 / 0.30 | 2.99 | 3.850E-07 | 2.28E-0.5 | |
| 0.04 / 0.03 | 0.47 / 0.37 | 2.22 | 0.0010 | 0.004 | |
| 0.21 / 0.19 | 1.90 / 1.33 | 4.96 | 6.67E-06 | 0.0001 | |
| 0.09 / 0.007 | 0.91 / 0.45 | 2.37 | 2.95E-0.6 | 8.83E-05 |
The log-fold changes (FC), p-value, false discovery rate (FDR), median expression values in reads per kilobase per million (RPKM) (Median), and the median absolute deviation (MAD) for LINC samples before and after GnRHa treatment are given
Testicular lincRNAs downregulated in HIR testes compared to LIR
| lincRNA | LIR | HIR | log2FC | FDR | |
|---|---|---|---|---|---|
| 0.47 0.17 | 0.10 0.07 | - 1.47 | 0.002 | 0.01 | |
| 0.64 0.27 | 0.27 0.07 | - 1.20 | 0.0007 | 0.008 | |
| 0.43 0.28 | 0.15 0.08 | - 1.42 | 0.001 | 0.01 | |
| 0.29 0.03 | 0.11 0.06 | - 0.84 | 0.002 | 0.02 | |
| 0.49 0.23 | 0.13 0.09 | - 1.74 | 0.0001 | 0.002 | |
| 0.42 0.09 | 0.20 0.06 | - 0.92 | 0.006 | 0.03 | |
| 0.57 0.09 | 0.31 0.08 | - 1.21 | 0.0002 | 0.003 |
The log-fold changes (FC), p-value, false discovery rate (FDR), median expression values in reads per kilobase per million (RPKM) (Median), and the median absolute deviation (MAD) for LINC samples are presented
LncNRAs downregulated in HIR testes and stimulated after GnRHa treatment
| lincRNA (RPKM) | before GnRHa | after GnRHa | log2FC | p-value | FDR |
|---|---|---|---|---|---|
| 0.10 0.07 | 0.85 0.40 | 1.41 | 0.02 | 0.04 | |
| 0.27 0.07 | 1.12 0.42 | 1.23 | 0.01 | 0.03 | |
| 0.15 0.08 | 0.92 0.56 | 1.38 | 0.003 | 0.01 | |
| 0.11 0.06 | 0.72 0.48 | 1.28 | 0.0009 | 0.003 | |
| 0.13 0.09 | 1.04 0.87 | 1.14 | 0.01 | 0.03 | |
| 0.20 0.06 | 1.13 0.81 | 2.02 | 1.55E-05 | 0.0002 | |
| 0.31 0.08 | 1.49 0.82 | 1.14 | 0.0007 | 0.003 |
The log-fold changes (FC), p-value, false discovery rate (FDR), median expression values in reads per kilobase per million (RPKM) (Median), and the median absolute deviation (MAD) for LINC samples before and after GnRHa treatment are shown
Seven epigenetic modifiers that bind TINCR
| Gene ID | Name | Log2FC HIR/LIR | FDR | Log2FC | FDR |
|---|---|---|---|---|---|
| SET domain containing lysine methyltransferase 7 | + 0.22 | 0.042 | −0.85 | 0.0006 | |
| AT-rich ineraction domain 4B | + 0.18 | 0.041 | −0.63 | 0.008 | |
| AT-rich interaction domain 5B | + 0.35 | 0.004 | −0.49 | 0.003 | |
| lysine demethylase 6A | + 0.20 | 0.017 | −0.81 | 0.0009 | |
| chromodomain helicase DNA binding protein 6 | + 0.21 | 0.040 | −0.54 | 0.03 | |
| methyl-CpG binding domain protein 2 | + 0.23 | 0.029 | −0.68 | 0.004 | |
| bromodomain PHD finger transcription factor | + 0.19 | 0.055 | −0.61 | 0.01 |
The log-fold changes (FC), p-value, false discovery rate (FDR), comparing HIR and LIR cryptorchid testes as well as results from HIR group following GnRHa treatment are presented